Biological roles of SLC16A1-AS1 lncRNA and its clinical impacts in tumors

Recent studies have increasingly highlighted the aberrant expression of SLC16A1-AS1 in a variety of tumor types, where it functions as either an oncogene or a tumor suppressor in the pathogenesis of different cancers. The expression levels of SLC16A1-AS1 have been found to significantly correlate wi...

Full description

Saved in:
Bibliographic Details
Published inCancer cell international Vol. 24; no. 1; pp. 122 - 12
Main Authors Liao, Bing, Wang, Jialing, Yuan, Yalin, Luo, Hongliang, Ouyang, Xi
Format Journal Article
LanguageEnglish
Published England BioMed Central 30.03.2024
BMC
Subjects
Apoptosis
Biomarkers
Brain cancer
Cancer biomarker
Cancer therapies
Cell cycle
Cell growth
CRISPR
Disease
Ferroptosis
Gene expression
Glioma
Human tumor
Kidney cancer
Liver cancer
Medical prognosis
Medical research
Metabolism
MicroRNAs
Review
Roles
SLC16A1-AS1
Squamous cell carcinoma
Therapeutic targets
Tumor suppressor genes
Tumorigenesis
Tumors
Cancer biomarker
SLC16A1-AS1
Tumorigenesis
Human tumor
Online AccessGet full text

Cover

Abstract Recent studies have increasingly highlighted the aberrant expression of SLC16A1-AS1 in a variety of tumor types, where it functions as either an oncogene or a tumor suppressor in the pathogenesis of different cancers. The expression levels of SLC16A1-AS1 have been found to significantly correlate with clinical features and the prognosis of cancer patients. Furthermore, SLC16A1-AS1 modulates a range of cellular functions, including proliferation, migration, and invasion, through its interactions with diverse molecules and signaling pathways. This review examines the latest evidence regarding the role of SLC16A1-AS1 in the progression of various tumors and explores its potential clinical applications as a novel prognostic and diagnostic biomarker. Our comprehensive review aims to deepen the understanding of SLC16A1-AS1’s multifaceted role in oncology, underscoring its potential as a significant biomarker and therapeutic target.
AbstractList Recent studies have increasingly highlighted the aberrant expression of SLC16A1-AS1 in a variety of tumor types, where it functions as either an oncogene or a tumor suppressor in the pathogenesis of different cancers. The expression levels of SLC16A1-AS1 have been found to significantly correlate with clinical features and the prognosis of cancer patients. Furthermore, SLC16A1-AS1 modulates a range of cellular functions, including proliferation, migration, and invasion, through its interactions with diverse molecules and signaling pathways. This review examines the latest evidence regarding the role of SLC16A1-AS1 in the progression of various tumors and explores its potential clinical applications as a novel prognostic and diagnostic biomarker. Our comprehensive review aims to deepen the understanding of SLC16A1-AS1's multifaceted role in oncology, underscoring its potential as a significant biomarker and therapeutic target.
Abstract Recent studies have increasingly highlighted the aberrant expression of SLC16A1-AS1 in a variety of tumor types, where it functions as either an oncogene or a tumor suppressor in the pathogenesis of different cancers. The expression levels of SLC16A1-AS1 have been found to significantly correlate with clinical features and the prognosis of cancer patients. Furthermore, SLC16A1-AS1 modulates a range of cellular functions, including proliferation, migration, and invasion, through its interactions with diverse molecules and signaling pathways. This review examines the latest evidence regarding the role of SLC16A1-AS1 in the progression of various tumors and explores its potential clinical applications as a novel prognostic and diagnostic biomarker. Our comprehensive review aims to deepen the understanding of SLC16A1-AS1’s multifaceted role in oncology, underscoring its potential as a significant biomarker and therapeutic target.
Recent studies have increasingly highlighted the aberrant expression of SLC16A1-AS1 in a variety of tumor types, where it functions as either an oncogene or a tumor suppressor in the pathogenesis of different cancers. The expression levels of SLC16A1-AS1 have been found to significantly correlate with clinical features and the prognosis of cancer patients. Furthermore, SLC16A1-AS1 modulates a range of cellular functions, including proliferation, migration, and invasion, through its interactions with diverse molecules and signaling pathways. This review examines the latest evidence regarding the role of SLC16A1-AS1 in the progression of various tumors and explores its potential clinical applications as a novel prognostic and diagnostic biomarker. Our comprehensive review aims to deepen the understanding of SLC16A1-AS1's multifaceted role in oncology, underscoring its potential as a significant biomarker and therapeutic target.Recent studies have increasingly highlighted the aberrant expression of SLC16A1-AS1 in a variety of tumor types, where it functions as either an oncogene or a tumor suppressor in the pathogenesis of different cancers. The expression levels of SLC16A1-AS1 have been found to significantly correlate with clinical features and the prognosis of cancer patients. Furthermore, SLC16A1-AS1 modulates a range of cellular functions, including proliferation, migration, and invasion, through its interactions with diverse molecules and signaling pathways. This review examines the latest evidence regarding the role of SLC16A1-AS1 in the progression of various tumors and explores its potential clinical applications as a novel prognostic and diagnostic biomarker. Our comprehensive review aims to deepen the understanding of SLC16A1-AS1's multifaceted role in oncology, underscoring its potential as a significant biomarker and therapeutic target.
ArticleNumber 122
Author Luo, Hongliang
Liao, Bing
Ouyang, Xi
Wang, Jialing
Yuan, Yalin
Author_xml – sequence: 1
  givenname: Bing
  surname: Liao
  fullname: Liao, Bing
– sequence: 2
  givenname: Jialing
  surname: Wang
  fullname: Wang, Jialing
– sequence: 3
  givenname: Yalin
  surname: Yuan
  fullname: Yuan, Yalin
– sequence: 4
  givenname: Hongliang
  surname: Luo
  fullname: Luo, Hongliang
– sequence: 5
  givenname: Xi
  surname: Ouyang
  fullname: Ouyang, Xi
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38555465$$D View this record in MEDLINE/PubMed
BookMark eNp9kkuP0zAQgC20iH3AH-CAInHhEvA4sWOfULfiUakCiYWz5Uzs4sqNi50g8e9x22W1uwdOtsbffBrPzCU5G-NoCXkJ9C2AFO8yMNXwmrK2pg2TvBZPyAW0Ha-ZFN3Zvfs5ucx5Syl0UtBn5LyRnPNW8AuyuvYxxI1HE6oUg81VdNXNegliAfXiBqow4rcvi8qMQ-WnXGHw4xH2u73BEvBjNc27mPJz8tSZkO2L2_OK_Pj44fvyc73--mm1XKxr5EpONWuxV-hY33LWmwGck7a3iKJHJwfTg5QOFaeWI7aDxU4hCEQHdrC8laK5IquTd4hmq_fJ70z6o6Px-hiIaaNNmjwGq0E2SoFDpFK0MPDeKANKDMw5oI6b4np_cu3nfmcHtOOUTHggffgy-p96E39roEoWOy2GN7eGFH_NNk965zPaEMxo45x1QxnjHYBgBX39CN3GOY2lV4VqymQko02hXt0v6a6WfyMrADsBmGLOybo7BKg-7IU-7YUue6GPe6EPTZOPktBPZvLx8C0f_pf6F03Zu-w
CitedBy_id crossref_primary_10_3390_ijms25168743
crossref_primary_10_62347_ABOI7514
Cites_doi 10.1016/j.cell.2012.03.042
10.1038/s41401-019-0322-9
10.3390/genes12081132
10.1016/j.tig.2016.08.004
10.1002/bies.200900170
10.1186/s12935-023-03037-y
10.1038/s41576-023-00662-1
10.1016/j.bbagrm.2015.07.014
10.1016/j.jbiotec.2023.12.003
10.18632/aging.102468
10.3389/fonc.2022.712475
10.1002/jcla.24813
10.1002/ctm2.1418
10.1126/science.abp9556
10.1080/15476286.2015.1063770
10.1007/s11356-020-09998-1
10.1158/0008-5472.CAN-14-3625
10.3390/antiox11122444
10.1186/s40001-023-01422-x
10.1007/978-1-0716-1581-2_4
10.1038/s41568-019-0149-1
10.1016/j.ymthe.2021.03.017
10.1038/nature08975
10.3390/ncrna7010003
10.1016/j.biopha.2023.115716
10.3389/fonc.2020.598817
10.1002/bies.950171004
10.1186/s12920-020-00757-2
10.1016/j.clinre.2020.07.001
10.1038/s41580-019-0123-5
10.1038/leu.2011.66
10.1159/000090831
10.1186/s12935-017-0434-6
10.1038/s41380-023-02377-5
10.1186/s12935-023-02867-0
10.3892/etm.2023.12169
10.1080/21655979.2022.2070581
10.7150/jca.49067
10.1016/j.phrs.2022.106549
10.1016/j.biopha.2019.109703
10.1016/j.cmet.2007.10.002
10.1016/j.clinbiochem.2020.06.005
10.1590/1806-9282.20210966
10.1126/science.aaw5473
10.1007/s00280-022-04401-x
10.1016/j.ejca.2013.04.026
10.1038/nsmb.2921
10.1080/21655979.2021.1996510
10.3389/fgene.2021.813873
10.1038/s41580-020-00315-9
10.1186/s12935-021-02168-4
10.1126/sciadv.aao2110
10.3892/or.2017.5840
10.1016/j.ijcard.2021.09.006
10.18632/aging.103034
10.1002/cam4.5872
10.3390/ncrna7020029
10.3389/fimmu.2022.904133
10.1016/j.exphem.2019.10.002
10.1038/s41420-021-00678-8
10.1186/1756-0500-6-518
10.1186/s12943-022-01530-y
10.1002/jcla.24442
10.7150/ijbs.40769
10.1158/0008-5472.CAN-16-2634
10.3390/ijms232314808
10.1186/s12935-022-02633-8
10.1038/s41580-022-00566-8
10.1038/leu.2008.27
10.1016/j.apsb.2020.10.001
10.1007/s00204-013-1122-5
10.3389/fendo.2017.00311
10.1186/s12935-021-02404-x
10.5603/FHC.2012.0026
10.1016/j.cell.2007.06.014
10.1016/j.biopha.2022.114060
10.1186/s12935-021-01926-8
10.1080/15476286.2021.1899500
10.1080/15384101.2015.1007767
10.1016/j.prp.2023.154957
10.1186/s12935-023-02849-2
10.1002/jcla.24344
10.1038/s41416-021-01600-w
10.7150/thno.44176
10.1002/jbt.23247
10.1002/2211-5463.12545
10.2144/000114037
10.1038/nm.3981
10.3389/fonc.2022.1025594
10.3389/fnmol.2021.714768
10.1038/s41568-021-00378-6
10.3390/cancers14102549
10.3390/cancers14051298
10.18632/oncotarget.11155
10.4161/rna.24604
10.1007/s13238-020-00789-5
10.1093/hmg/ddl046
10.1038/s41419-021-03595-x
10.1080/08923973.2022.2056482
10.1186/s12885-022-09282-0
10.1016/j.ncrna.2016.11.002
10.1177/15330338221077803
10.7150/thno.71144
10.1016/j.yexcr.2022.113294
10.1016/j.jep.2021.114017
10.1007/s10266-022-00712-w
10.7717/peerj.13641
10.1111/cpr.12404
10.1093/nar/gkz430
10.1016/j.cell.2007.05.022
10.1038/s41392-021-00779-x
10.1038/s41388-019-1040-y
10.1080/15384101.2020.1762048
10.3892/ol.2021.12563
10.1186/s40001-022-00745-5
10.1016/j.jbc.2022.102630
10.1136/jim-2019-001080
10.4161/epi.5.4.11637
10.3390/cells10051056
10.3389/fendo.2016.00151
10.1007/978-3-319-53889-1_18
10.1016/j.cca.2019.12.028
10.1186/s12935-023-03018-1
10.1186/s12935-023-02986-8
10.4161/cc.9.17.13122
10.1007/978-3-030-92034-0_9
10.1016/j.freeradbiomed.2018.09.043
10.1042/BSR20192453
10.1186/s12935-021-01841-y
10.2217/fon.15.258
10.1016/j.ygeno.2008.11.009
10.1007/978-981-10-5203-3_1
10.1002/mrd.23728
10.1016/j.semcancer.2021.03.029
10.1188/16.CJON.S1.2-8
10.1016/j.neuroscience.2023.02.016
10.1038/s41419-022-04832-7
10.2147/CMAR.S276629
10.1186/s12935-023-02872-3
10.18632/oncotarget.18633
10.2147/CMAR.S264613
10.2174/0929867330666230111125141
10.7554/eLife.79126
10.1186/s12935-022-02817-2
10.1186/s12935-023-03194-0
10.3390/cells13020119
10.1038/cgt.2017.10
10.3389/fchem.2023.1335330
10.3390/metabo11010028
ContentType Journal Article
Copyright 2024. The Author(s).
2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2024
Copyright_xml – notice: 2024. The Author(s).
– notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2024
DBID AAYXX
CITATION
NPM
3V.
7TM
7TO
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12935-024-03285-6
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
Nucleic Acids Abstracts
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList PubMed

MEDLINE - Academic
CrossRef

Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1475-2867
EndPage 12
ExternalDocumentID oai_doaj_org_article_183991fcc08641d5ba9a196d2ff10f5a
PMC10981830
38555465
10_1186_s12935_024_03285_6
Genre Journal Article
Review
GrantInformation_xml – fundername: Natural Science Foundation of Jiangxi Province
  grantid: 20232BAB206118
– fundername: National Natural Science Foundation of China
  grantid: No.82060279
GroupedDBID ---
0R~
29B
2WC
53G
5GY
5VS
6J9
7X7
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACMJI
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
ISR
ITC
KQ8
LGEZI
LOTEE
M48
M~E
NADUK
NXXTH
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
~8M
NPM
3V.
7TM
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c598t-24cb9cf2b452bad1ff8ebecc6bcf8dab188fc950e5cc4dec79c16ccf1ede54863
IEDL.DBID M48
ISSN 1475-2867
IngestDate Wed Aug 27 01:16:25 EDT 2025
Thu Aug 21 18:34:59 EDT 2025
Thu Jul 10 22:43:50 EDT 2025
Mon Jun 30 03:52:27 EDT 2025
Mon Jul 21 05:59:54 EDT 2025
Thu Apr 24 23:00:11 EDT 2025
Tue Jul 01 02:41:59 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Cancer biomarker
SLC16A1-AS1
Tumorigenesis
Human tumor
Language English
License 2024. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c598t-24cb9cf2b452bad1ff8ebecc6bcf8dab188fc950e5cc4dec79c16ccf1ede54863
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12935-024-03285-6
PMID 38555465
PQID 3037868203
PQPubID 42567
PageCount 12
ParticipantIDs doaj_primary_oai_doaj_org_article_183991fcc08641d5ba9a196d2ff10f5a
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10981830
proquest_miscellaneous_3022571162
proquest_journals_3037868203
pubmed_primary_38555465
crossref_primary_10_1186_s12935_024_03285_6
crossref_citationtrail_10_1186_s12935_024_03285_6
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-03-30
PublicationDateYYYYMMDD 2024-03-30
PublicationDate_xml – month: 03
  year: 2024
  text: 2024-03-30
  day: 30
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Cancer cell international
PublicationTitleAlternate Cancer Cell Int
PublicationYear 2024
Publisher BioMed Central
BMC
Publisher_xml – name: BioMed Central
– name: BMC
References A Gabory (3285_CR41) 2006; 113
L Chen (3285_CR36) 2021; 21
X Pan (3285_CR16) 2023; 23
H Wang (3285_CR142) 2022; 10
JB Pierce (3285_CR72) 2022; 1363
YZ Li (3285_CR101) 2022; 21
B Signal (3285_CR13) 2016; 32
3285_CR33
Y Chen (3285_CR71) 2021; 11
F Jian (3285_CR132) 2021; 12
3285_CR107
N Lv (3285_CR66) 2023; 23
SZ M (3285_CR77) 2021; 18
C Li (3285_CR54) 2021; 6
3285_CR122
J Bohosova (3285_CR146) 2022; 36
W Bian (3285_CR58) 2020; 12
T Li (3285_CR95) 2023; 111
JM Perkel (3285_CR6) 2013; 54
M Ghasemian (3285_CR53) 2023; 23
B Liu (3285_CR89) 2021; 21
ME Davis (3285_CR110) 2016; 20
J Ouyang (3285_CR68) 2022; 126
I Martínez-Reyes (3285_CR123) 2021; 21
RA Gupta (3285_CR35) 2010; 464
C Vitali (3285_CR131) 2015; 75
Z Jin (3285_CR93) 2022; 13
S Logotheti (3285_CR102) 2020; 10
3285_CR47
S Najafi (3285_CR69) 2022; 418
S Zhao (3285_CR2) 2021; 7
C Zhang (3285_CR148) 2022; 21
J Zhu (3285_CR125) 2019; 20
E Domingo-Musibay (3285_CR111) 2015; 11
S Viville (3285_CR42) 1995; 17
M Song (3285_CR100) 2019; 11
3285_CR114
JP Friedmann Angeli (3285_CR149) 2019; 19
Y Wu (3285_CR15) 2023; 23
J Tian (3285_CR97) 2021; 45
M Hajjari (3285_CR23) 2015; 12
H Zhang (3285_CR103) 2021; 13
R Policarpo (3285_CR80) 2021; 14
T Rajagopal (3285_CR22) 2020; 503
L Yu (3285_CR44) 2017; 24
CJ Woo (3285_CR20) 2007; 129
K Nemeth (3285_CR73) 2024; 25
Y Wan (3285_CR34) 2010; 9
A Poursheikhani (3285_CR139) 2022; 22
A Poursheikhani (3285_CR140) 2020; 13
J Zhang (3285_CR45) 2023; 23
3285_CR19
Y Li (3285_CR59) 2023; 529
N Gao (3285_CR9) 2020; 10
RK Mahato (3285_CR76) 2024; 379
L Statello (3285_CR84) 2021; 22
SU Rehman (3285_CR92) 2023; 11
Y Long (3285_CR94) 2021; 13
B Jiang (3285_CR106) 2022; 44
JA McCubrey (3285_CR137) 2008; 22
S Balusu (3285_CR60) 2023; 381
J Iwakiri (3285_CR14) 2016; 1859
B Jiang (3285_CR105) 2022; 12
W Wan (3285_CR135) 2022; 89
K Wang (3285_CR32) 2024; 24
PS Wang (3285_CR51) 2021; 76
A Gabory (3285_CR40) 2010; 32
M Ghasemian (3285_CR55) 2022; 22
H Yousefi (3285_CR82) 2020; 39
S Pei (3285_CR98) 2020; 27
Q Yin (3285_CR154) 2019; 79
Y Gong (3285_CR10) 2021; 12
P Han (3285_CR86) 2015; 12
P Koppula (3285_CR115) 2021; 12
SA Bhat (3285_CR85) 2016; 1
W Yin (3285_CR130) 2019; 9
Z Tang (3285_CR144) 2019; 47
J Wang (3285_CR27) 2022; 298
MZ Ratajczak (3285_CR38) 2012; 50
C Shen (3285_CR121) 2020; 23
ML Zu (3285_CR119) 2021; 273
3285_CR150
H Feng (3285_CR96) 2020; 19
S Wei (3285_CR31) 2017; 38
P Huang (3285_CR129) 2022; 12
L Agnelli (3285_CR11) 2021; 2348
F Liu (3285_CR67) 2017; 8
M Gong (3285_CR141) 2023; 28
ZD Zhang (3285_CR4) 2023; 26
S Gao (3285_CR118) 2022; 13
FT Liu (3285_CR70) 2016; 7
3285_CR75
M Sadeghalvad (3285_CR28) 2022; 68
J Yang (3285_CR63) 2022; 186
HY Liu (3285_CR108) 2020; 68
M Hu (3285_CR30) 2020; 125
S Liu (3285_CR145) 2022; 27
FC Kuo (3285_CR24) 2022; 22
R Maoz (3285_CR61) 2017; 978
Y Ma (3285_CR56) 2023; 30
W Lin (3285_CR46) 2020; 16
Y Guo (3285_CR48) 2021; 21
3285_CR83
J Feng (3285_CR43) 2023; 12
JL Rinn (3285_CR21) 2007; 129
3285_CR87
R Louro (3285_CR7) 2009; 93
C Chu (3285_CR12) 2015; 22
SP Hu (3285_CR17) 2021; 21
Y Ma (3285_CR29) 2019; 18
X Zhao (3285_CR104) 2023; 37
D Chen (3285_CR49) 2023; 13
JS Mattick (3285_CR79) 2023; 24
Y Mao (3285_CR57) 2021; 343
YT Chan (3285_CR78) 2022; 12
S Ren (3285_CR152) 2013; 49
JQ Zhu (3285_CR37) 2014; 88
PD Denechaud (3285_CR117) 2017; 8
J Jarroux (3285_CR5) 2017; 1008
M Zhou (3285_CR90) 2021; 12
3285_CR52
S Tabano (3285_CR39) 2010; 5
U Degirmenci (3285_CR50) 2016; 7
G Wang (3285_CR109) 2022; 13
Y Long (3285_CR88) 2017; 3
JJ Cabrera-Galván (3285_CR133) 2023; 157
L Zhang (3285_CR18) 2024; 91
L Ma (3285_CR81) 2013; 10
A Bhan (3285_CR91) 2017; 77
LS Steelman (3285_CR136) 2011; 25
X Zhou (3285_CR143) 2023; 37
MA Hakami (3285_CR26) 2024; 253
M Huarte (3285_CR1) 2015; 21
Y Xu (3285_CR3) 2021; 29
SJ Dixon (3285_CR112) 2012; 149
3285_CR124
3285_CR126
HT Lei (3285_CR62) 2023; 168
J Li (3285_CR25) 2017; 17
H Xing (3285_CR74) 2020; 41
W Lin (3285_CR116) 2020; 10
B Wang (3285_CR128) 2015; 14
3285_CR64
DG Weber (3285_CR151) 2013; 6
3285_CR138
T Hirschhorn (3285_CR113) 2019; 133
RJ DeBerardinis (3285_CR127) 2008; 7
C Duan (3285_CR99) 2022; 36
P Li (3285_CR120) 2021; 12
3285_CR134
Y Xiong (3285_CR147) 2021; 21
M Mohyeldeen (3285_CR153) 2020; 84
3285_CR8
H Zeng (3285_CR65) 2023; 23
References_xml – volume: 149
  start-page: 1060
  issue: 5
  year: 2012
  ident: 3285_CR112
  publication-title: Cell
  doi: 10.1016/j.cell.2012.03.042
– volume: 41
  start-page: 583
  issue: 5
  year: 2020
  ident: 3285_CR74
  publication-title: Acta Pharmacol Sin
  doi: 10.1038/s41401-019-0322-9
– ident: 3285_CR107
  doi: 10.3390/genes12081132
– volume: 23
  start-page: 921
  issue: 10
  year: 2020
  ident: 3285_CR121
  publication-title: Zhongguo Fei Ai Za Zhi
– volume: 32
  start-page: 620
  issue: 10
  year: 2016
  ident: 3285_CR13
  publication-title: Trends Genet
  doi: 10.1016/j.tig.2016.08.004
– volume: 32
  start-page: 473
  issue: 6
  year: 2010
  ident: 3285_CR40
  publication-title: BioEssays
  doi: 10.1002/bies.200900170
– volume: 23
  start-page: 184
  issue: 1
  year: 2023
  ident: 3285_CR53
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-023-03037-y
– volume: 12
  start-page: 1
  issue: 1
  year: 2015
  ident: 3285_CR23
  publication-title: Cancer Biol Med
– volume: 25
  start-page: 211
  issue: 3
  year: 2024
  ident: 3285_CR73
  publication-title: Nat Rev Genet
  doi: 10.1038/s41576-023-00662-1
– volume: 1859
  start-page: 23
  issue: 1
  year: 2016
  ident: 3285_CR14
  publication-title: Biochim Biophys Acta
  doi: 10.1016/j.bbagrm.2015.07.014
– volume: 379
  start-page: 98
  year: 2024
  ident: 3285_CR76
  publication-title: J Biotechnol
  doi: 10.1016/j.jbiotec.2023.12.003
– volume: 11
  start-page: 10422
  issue: 22
  year: 2019
  ident: 3285_CR100
  publication-title: Aging
  doi: 10.18632/aging.102468
– volume: 12
  start-page: 712475
  year: 2022
  ident: 3285_CR105
  publication-title: Front Oncol
  doi: 10.3389/fonc.2022.712475
– volume: 37
  start-page: e24813
  issue: 1
  year: 2023
  ident: 3285_CR143
  publication-title: J Clin Lab Anal
  doi: 10.1002/jcla.24813
– volume: 13
  start-page: e1418
  issue: 9
  year: 2023
  ident: 3285_CR49
  publication-title: Clin Transl Med
  doi: 10.1002/ctm2.1418
– volume: 381
  start-page: 1176
  issue: 6663
  year: 2023
  ident: 3285_CR60
  publication-title: Science
  doi: 10.1126/science.abp9556
– volume: 12
  start-page: 1094
  issue: 10
  year: 2015
  ident: 3285_CR86
  publication-title: RNA Biol
  doi: 10.1080/15476286.2015.1063770
– volume: 27
  start-page: 42778
  issue: 34
  year: 2020
  ident: 3285_CR98
  publication-title: Environ Sci Pollut Res Int
  doi: 10.1007/s11356-020-09998-1
– volume: 75
  start-page: 2387
  issue: 11
  year: 2015
  ident: 3285_CR131
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-14-3625
– ident: 3285_CR114
  doi: 10.3390/antiox11122444
– volume: 28
  start-page: 440
  issue: 1
  year: 2023
  ident: 3285_CR141
  publication-title: Eur J Med Res
  doi: 10.1186/s40001-023-01422-x
– volume: 2348
  start-page: 55
  year: 2021
  ident: 3285_CR11
  publication-title: Methods Mol Biol
  doi: 10.1007/978-1-0716-1581-2_4
– volume: 19
  start-page: 405
  issue: 7
  year: 2019
  ident: 3285_CR149
  publication-title: Nat Rev Cancer
  doi: 10.1038/s41568-019-0149-1
– volume: 29
  start-page: 2209
  issue: 7
  year: 2021
  ident: 3285_CR3
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2021.03.017
– volume: 464
  start-page: 1071
  issue: 7291
  year: 2010
  ident: 3285_CR35
  publication-title: Nature
  doi: 10.1038/nature08975
– ident: 3285_CR83
  doi: 10.3390/ncrna7010003
– volume: 168
  start-page: 115716
  year: 2023
  ident: 3285_CR62
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2023.115716
– volume: 10
  start-page: 598817
  year: 2020
  ident: 3285_CR9
  publication-title: Front Oncol
  doi: 10.3389/fonc.2020.598817
– volume: 17
  start-page: 835
  issue: 10
  year: 1995
  ident: 3285_CR42
  publication-title: BioEssays
  doi: 10.1002/bies.950171004
– volume: 13
  start-page: 108
  issue: 1
  year: 2020
  ident: 3285_CR140
  publication-title: BMC Med Genomics
  doi: 10.1186/s12920-020-00757-2
– volume: 45
  start-page: 101490
  issue: 2
  year: 2021
  ident: 3285_CR97
  publication-title: Clin Res Hepatol Gastroenterol
  doi: 10.1016/j.clinre.2020.07.001
– volume: 20
  start-page: 436
  issue: 7
  year: 2019
  ident: 3285_CR125
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/s41580-019-0123-5
– volume: 10
  start-page: 3106
  issue: 10
  year: 2020
  ident: 3285_CR116
  publication-title: Am J Cancer Res
– volume: 25
  start-page: 1080
  issue: 7
  year: 2011
  ident: 3285_CR136
  publication-title: Leukemia
  doi: 10.1038/leu.2011.66
– volume: 113
  start-page: 188
  issue: 1–4
  year: 2006
  ident: 3285_CR41
  publication-title: Cytogenet Genome Res
  doi: 10.1159/000090831
– volume: 17
  start-page: 65
  year: 2017
  ident: 3285_CR25
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-017-0434-6
– ident: 3285_CR75
  doi: 10.1038/s41380-023-02377-5
– volume: 23
  start-page: 28
  issue: 1
  year: 2023
  ident: 3285_CR15
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-023-02867-0
– volume: 26
  start-page: 470
  issue: 4
  year: 2023
  ident: 3285_CR4
  publication-title: Exp Ther Med
  doi: 10.3892/etm.2023.12169
– volume: 13
  start-page: 12749
  issue: 5
  year: 2022
  ident: 3285_CR93
  publication-title: Bioengineered
  doi: 10.1080/21655979.2022.2070581
– volume: 12
  start-page: 1499
  issue: 5
  year: 2021
  ident: 3285_CR90
  publication-title: J Cancer
  doi: 10.7150/jca.49067
– volume: 186
  start-page: 106549
  year: 2022
  ident: 3285_CR63
  publication-title: Pharmacol Res
  doi: 10.1016/j.phrs.2022.106549
– volume: 125
  start-page: 109703
  year: 2020
  ident: 3285_CR30
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2019.109703
– volume: 7
  start-page: 11
  issue: 1
  year: 2008
  ident: 3285_CR127
  publication-title: Cell Metabol
  doi: 10.1016/j.cmet.2007.10.002
– volume: 84
  start-page: 38
  year: 2020
  ident: 3285_CR153
  publication-title: Clin Biochem
  doi: 10.1016/j.clinbiochem.2020.06.005
– volume: 68
  start-page: 456
  issue: 4
  year: 2022
  ident: 3285_CR28
  publication-title: Rev Assoc Med Bras (1992)
  doi: 10.1590/1806-9282.20210966
– ident: 3285_CR124
  doi: 10.1126/science.aaw5473
– volume: 89
  start-page: 401
  issue: 3
  year: 2022
  ident: 3285_CR135
  publication-title: Cancer Chemother Pharmacol
  doi: 10.1007/s00280-022-04401-x
– volume: 49
  start-page: 2949
  issue: 13
  year: 2013
  ident: 3285_CR152
  publication-title: Eur J Cancer
  doi: 10.1016/j.ejca.2013.04.026
– volume: 22
  start-page: 29
  issue: 1
  year: 2015
  ident: 3285_CR12
  publication-title: Nat Struct Mol Biol
  doi: 10.1038/nsmb.2921
– volume: 12
  start-page: 10047
  issue: 2
  year: 2021
  ident: 3285_CR120
  publication-title: Bioengineered
  doi: 10.1080/21655979.2021.1996510
– volume: 12
  start-page: 813873
  year: 2021
  ident: 3285_CR10
  publication-title: Front Genet
  doi: 10.3389/fgene.2021.813873
– volume: 22
  start-page: 96
  issue: 2
  year: 2021
  ident: 3285_CR84
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/s41580-020-00315-9
– volume: 21
  start-page: 459
  issue: 1
  year: 2021
  ident: 3285_CR89
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-021-02168-4
– volume: 3
  start-page: eaao2110
  issue: 9
  year: 2017
  ident: 3285_CR88
  publication-title: Sci Adv
  doi: 10.1126/sciadv.aao2110
– volume: 38
  start-page: 1902
  issue: 3
  year: 2017
  ident: 3285_CR31
  publication-title: Oncol Rep
  doi: 10.3892/or.2017.5840
– volume: 343
  start-page: 106
  year: 2021
  ident: 3285_CR57
  publication-title: Int J Cardiol
  doi: 10.1016/j.ijcard.2021.09.006
– volume: 12
  start-page: 6385
  issue: 7
  year: 2020
  ident: 3285_CR58
  publication-title: Aging
  doi: 10.18632/aging.103034
– volume: 12
  start-page: 11971
  issue: 10
  year: 2023
  ident: 3285_CR43
  publication-title: Cancer Med
  doi: 10.1002/cam4.5872
– ident: 3285_CR87
  doi: 10.3390/ncrna7020029
– volume: 13
  start-page: 904133
  year: 2022
  ident: 3285_CR109
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2022.904133
– volume: 79
  start-page: 47
  year: 2019
  ident: 3285_CR154
  publication-title: Exp Hematol
  doi: 10.1016/j.exphem.2019.10.002
– volume: 7
  start-page: 283
  issue: 1
  year: 2021
  ident: 3285_CR2
  publication-title: Cell Death Discov
  doi: 10.1038/s41420-021-00678-8
– volume: 6
  start-page: 518
  year: 2013
  ident: 3285_CR151
  publication-title: BMC Res Notes
  doi: 10.1186/1756-0500-6-518
– volume: 21
  start-page: 47
  issue: 1
  year: 2022
  ident: 3285_CR148
  publication-title: Mol Cancer
  doi: 10.1186/s12943-022-01530-y
– volume: 36
  start-page: e24442
  issue: 6
  year: 2022
  ident: 3285_CR146
  publication-title: J Clin Lab Anal
  doi: 10.1002/jcla.24442
– volume: 16
  start-page: 1194
  issue: 7
  year: 2020
  ident: 3285_CR46
  publication-title: Int J Biol Sci
  doi: 10.7150/ijbs.40769
– volume: 77
  start-page: 3965
  issue: 15
  year: 2017
  ident: 3285_CR91
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-16-2634
– ident: 3285_CR150
  doi: 10.3390/ijms232314808
– volume: 22
  start-page: 215
  issue: 1
  year: 2022
  ident: 3285_CR55
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-022-02633-8
– volume: 24
  start-page: 430
  issue: 6
  year: 2023
  ident: 3285_CR79
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/s41580-022-00566-8
– volume: 22
  start-page: 708
  issue: 4
  year: 2008
  ident: 3285_CR137
  publication-title: Leukemia
  doi: 10.1038/leu.2008.27
– volume: 11
  start-page: 340
  issue: 2
  year: 2021
  ident: 3285_CR71
  publication-title: Acta Pharm Sin B
  doi: 10.1016/j.apsb.2020.10.001
– volume: 88
  start-page: 241
  issue: 2
  year: 2014
  ident: 3285_CR37
  publication-title: Arch Toxicol
  doi: 10.1007/s00204-013-1122-5
– volume: 8
  start-page: 311
  year: 2017
  ident: 3285_CR117
  publication-title: Front Endocrinol (Lausanne)
  doi: 10.3389/fendo.2017.00311
– volume: 21
  start-page: 686
  issue: 1
  year: 2021
  ident: 3285_CR17
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-021-02404-x
– volume: 50
  start-page: 171
  issue: 2
  year: 2012
  ident: 3285_CR38
  publication-title: Folia Histochem Cytobiol
  doi: 10.5603/FHC.2012.0026
– volume: 129
  start-page: 1257
  issue: 7
  year: 2007
  ident: 3285_CR20
  publication-title: Cell
  doi: 10.1016/j.cell.2007.06.014
– volume: 157
  start-page: 114060
  year: 2023
  ident: 3285_CR133
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2022.114060
– volume: 21
  start-page: 209
  issue: 1
  year: 2021
  ident: 3285_CR48
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-021-01926-8
– volume: 18
  start-page: 2097
  issue: 12
  year: 2021
  ident: 3285_CR77
  publication-title: RNA Biol
  doi: 10.1080/15476286.2021.1899500
– volume: 14
  start-page: 1046
  issue: 7
  year: 2015
  ident: 3285_CR128
  publication-title: Cell Cycle
  doi: 10.1080/15384101.2015.1007767
– volume: 253
  start-page: 154957
  year: 2024
  ident: 3285_CR26
  publication-title: Pathol Res Pract
  doi: 10.1016/j.prp.2023.154957
– volume: 23
  start-page: 4
  issue: 1
  year: 2023
  ident: 3285_CR66
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-023-02849-2
– volume: 36
  start-page: e24344
  issue: 4
  year: 2022
  ident: 3285_CR99
  publication-title: J Clin Lab Anal
  doi: 10.1002/jcla.24344
– volume: 126
  start-page: 1113
  issue: 8
  year: 2022
  ident: 3285_CR68
  publication-title: Br J Cancer
  doi: 10.1038/s41416-021-01600-w
– volume: 10
  start-page: 9620
  issue: 21
  year: 2020
  ident: 3285_CR102
  publication-title: Theranostics
  doi: 10.7150/thno.44176
– volume: 37
  start-page: e23247
  issue: 3
  year: 2023
  ident: 3285_CR104
  publication-title: J Biochem Mol Toxicol
  doi: 10.1002/jbt.23247
– volume: 9
  start-page: 43
  issue: 1
  year: 2019
  ident: 3285_CR130
  publication-title: FEBS Open Bio
  doi: 10.1002/2211-5463.12545
– volume: 54
  start-page: 301
  issue: 6
  year: 2013
  ident: 3285_CR6
  publication-title: Biotechniques
  doi: 10.2144/000114037
– volume: 21
  start-page: 1253
  issue: 11
  year: 2015
  ident: 3285_CR1
  publication-title: Nat Med
  doi: 10.1038/nm.3981
– volume: 12
  start-page: 1025594
  year: 2022
  ident: 3285_CR129
  publication-title: Front Oncol
  doi: 10.3389/fonc.2022.1025594
– volume: 14
  start-page: 714768
  year: 2021
  ident: 3285_CR80
  publication-title: Front Mol Neurosci
  doi: 10.3389/fnmol.2021.714768
– volume: 21
  start-page: 669
  issue: 10
  year: 2021
  ident: 3285_CR123
  publication-title: Nat Rev Cancer
  doi: 10.1038/s41568-021-00378-6
– ident: 3285_CR134
  doi: 10.3390/cancers14102549
– ident: 3285_CR138
  doi: 10.3390/cancers14051298
– volume: 7
  start-page: 57991
  issue: 36
  year: 2016
  ident: 3285_CR70
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.11155
– volume: 10
  start-page: 925
  issue: 6
  year: 2013
  ident: 3285_CR81
  publication-title: RNA Biol
  doi: 10.4161/rna.24604
– volume: 12
  start-page: 599
  issue: 8
  year: 2021
  ident: 3285_CR115
  publication-title: Protein Cell
  doi: 10.1007/s13238-020-00789-5
– ident: 3285_CR8
  doi: 10.1093/hmg/ddl046
– volume: 12
  start-page: 351
  issue: 4
  year: 2021
  ident: 3285_CR132
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-021-03595-x
– volume: 18
  start-page: 2212
  issue: 3
  year: 2019
  ident: 3285_CR29
  publication-title: Oncol Lett
– volume: 44
  start-page: 534
  issue: 4
  year: 2022
  ident: 3285_CR106
  publication-title: Immunopharmacol Immunotoxicol
  doi: 10.1080/08923973.2022.2056482
– volume: 22
  start-page: 196
  issue: 1
  year: 2022
  ident: 3285_CR139
  publication-title: BMC Cancer
  doi: 10.1186/s12885-022-09282-0
– volume: 1
  start-page: 43
  issue: 1
  year: 2016
  ident: 3285_CR85
  publication-title: Noncoding RNA Res
  doi: 10.1016/j.ncrna.2016.11.002
– volume: 21
  start-page: 153303382210778
  year: 2022
  ident: 3285_CR101
  publication-title: Technol Cancer Res Treat
  doi: 10.1177/15330338221077803
– volume: 12
  start-page: 3329
  issue: 7
  year: 2022
  ident: 3285_CR78
  publication-title: Theranostics
  doi: 10.7150/thno.71144
– volume: 418
  start-page: 113294
  issue: 2
  year: 2022
  ident: 3285_CR69
  publication-title: Exp Cell Res
  doi: 10.1016/j.yexcr.2022.113294
– volume: 273
  start-page: 114017
  year: 2021
  ident: 3285_CR119
  publication-title: J Ethnopharmacol
  doi: 10.1016/j.jep.2021.114017
– volume: 111
  start-page: 41
  issue: 1
  year: 2023
  ident: 3285_CR95
  publication-title: Odontology
  doi: 10.1007/s10266-022-00712-w
– volume: 10
  start-page: e13641
  year: 2022
  ident: 3285_CR142
  publication-title: PeerJ
  doi: 10.7717/peerj.13641
– ident: 3285_CR64
  doi: 10.1111/cpr.12404
– volume: 47
  start-page: W556
  issue: W1
  year: 2019
  ident: 3285_CR144
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkz430
– volume: 129
  start-page: 1311
  issue: 7
  year: 2007
  ident: 3285_CR21
  publication-title: Cell
  doi: 10.1016/j.cell.2007.05.022
– volume: 6
  start-page: 383
  issue: 1
  year: 2021
  ident: 3285_CR54
  publication-title: Signal Transduct Target Ther
  doi: 10.1038/s41392-021-00779-x
– ident: 3285_CR52
  doi: 10.1038/s41576-023-00662-1
– volume: 39
  start-page: 953
  issue: 5
  year: 2020
  ident: 3285_CR82
  publication-title: Oncogene
  doi: 10.1038/s41388-019-1040-y
– volume: 19
  start-page: 1641
  issue: 13
  year: 2020
  ident: 3285_CR96
  publication-title: Cell Cycle
  doi: 10.1080/15384101.2020.1762048
– volume: 21
  start-page: 302
  issue: 4
  year: 2021
  ident: 3285_CR36
  publication-title: Oncol Lett
  doi: 10.3892/ol.2021.12563
– volume: 27
  start-page: 122
  issue: 1
  year: 2022
  ident: 3285_CR145
  publication-title: Eur J Med Res
  doi: 10.1186/s40001-022-00745-5
– volume: 298
  start-page: 102630
  issue: 12
  year: 2022
  ident: 3285_CR27
  publication-title: J Biol Chem
  doi: 10.1016/j.jbc.2022.102630
– volume: 68
  start-page: 52
  issue: 1
  year: 2020
  ident: 3285_CR108
  publication-title: J Investig Med
  doi: 10.1136/jim-2019-001080
– volume: 5
  start-page: 313
  issue: 4
  year: 2010
  ident: 3285_CR39
  publication-title: Epigenetics
  doi: 10.4161/epi.5.4.11637
– ident: 3285_CR126
  doi: 10.3390/cells10051056
– volume: 7
  start-page: 151
  year: 2016
  ident: 3285_CR50
  publication-title: Front Endocrinol (Lausanne)
  doi: 10.3389/fendo.2016.00151
– volume: 978
  start-page: 337
  year: 2017
  ident: 3285_CR61
  publication-title: Adv Exp Med Biol
  doi: 10.1007/978-3-319-53889-1_18
– volume: 503
  start-page: 1
  year: 2020
  ident: 3285_CR22
  publication-title: Clin Chim Acta
  doi: 10.1016/j.cca.2019.12.028
– volume: 23
  start-page: 198
  issue: 1
  year: 2023
  ident: 3285_CR65
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-023-03018-1
– volume: 23
  start-page: 142
  issue: 1
  year: 2023
  ident: 3285_CR45
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-023-02986-8
– volume: 9
  start-page: 3391
  issue: 17
  year: 2010
  ident: 3285_CR34
  publication-title: Cell Cycle
  doi: 10.4161/cc.9.17.13122
– volume: 1363
  start-page: 161
  year: 2022
  ident: 3285_CR72
  publication-title: Adv Exp Med Biol
  doi: 10.1007/978-3-030-92034-0_9
– volume: 133
  start-page: 130
  year: 2019
  ident: 3285_CR113
  publication-title: Free Radic Biol Med
  doi: 10.1016/j.freeradbiomed.2018.09.043
– ident: 3285_CR47
  doi: 10.1042/BSR20192453
– volume: 21
  start-page: 233
  issue: 1
  year: 2021
  ident: 3285_CR147
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-021-01841-y
– volume: 11
  start-page: 3273
  issue: 24
  year: 2015
  ident: 3285_CR111
  publication-title: Future Oncol
  doi: 10.2217/fon.15.258
– volume: 93
  start-page: 291
  issue: 4
  year: 2009
  ident: 3285_CR7
  publication-title: Genomics
  doi: 10.1016/j.ygeno.2008.11.009
– volume: 1008
  start-page: 1
  year: 2017
  ident: 3285_CR5
  publication-title: Adv Exp Med Biol
  doi: 10.1007/978-981-10-5203-3_1
– volume: 91
  start-page: e23728
  issue: 1
  year: 2024
  ident: 3285_CR18
  publication-title: Mol Reprod Dev
  doi: 10.1002/mrd.23728
– volume: 76
  start-page: 163
  year: 2021
  ident: 3285_CR51
  publication-title: Semin Cancer Biol
  doi: 10.1016/j.semcancer.2021.03.029
– volume: 20
  start-page: S2
  issue: 5 Suppl
  year: 2016
  ident: 3285_CR110
  publication-title: Clin J Oncol Nurs
  doi: 10.1188/16.CJON.S1.2-8
– volume: 529
  start-page: 88
  year: 2023
  ident: 3285_CR59
  publication-title: Neuroscience
  doi: 10.1016/j.neuroscience.2023.02.016
– volume: 13
  start-page: 376
  issue: 4
  year: 2022
  ident: 3285_CR118
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-022-04832-7
– volume: 13
  start-page: 1299
  year: 2021
  ident: 3285_CR103
  publication-title: Cancer Manag Res
  doi: 10.2147/CMAR.S276629
– volume: 23
  start-page: 30
  issue: 1
  year: 2023
  ident: 3285_CR16
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-023-02872-3
– volume: 8
  start-page: 61561
  issue: 37
  year: 2017
  ident: 3285_CR67
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.18633
– volume: 13
  start-page: 1215
  year: 2021
  ident: 3285_CR94
  publication-title: Cancer Manag Res
  doi: 10.2147/CMAR.S264613
– volume: 30
  start-page: 4340
  issue: 38
  year: 2023
  ident: 3285_CR56
  publication-title: Curr Med Chem
  doi: 10.2174/0929867330666230111125141
– ident: 3285_CR33
  doi: 10.7554/eLife.79126
– volume: 22
  start-page: 396
  issue: 1
  year: 2022
  ident: 3285_CR24
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-022-02817-2
– volume: 24
  start-page: 15
  issue: 1
  year: 2024
  ident: 3285_CR32
  publication-title: Cancer Cell Int
  doi: 10.1186/s12935-023-03194-0
– ident: 3285_CR19
  doi: 10.3390/cells13020119
– volume: 24
  start-page: 221
  issue: 5
  year: 2017
  ident: 3285_CR44
  publication-title: Cancer Gene Ther
  doi: 10.1038/cgt.2017.10
– volume: 11
  start-page: 1335330
  year: 2023
  ident: 3285_CR92
  publication-title: Front Chem
  doi: 10.3389/fchem.2023.1335330
– ident: 3285_CR122
  doi: 10.3390/metabo11010028
SSID ssj0017860
Score 2.3487384
SecondaryResourceType review_article
Snippet Recent studies have increasingly highlighted the aberrant expression of SLC16A1-AS1 in a variety of tumor types, where it functions as either an oncogene or a...
Abstract Recent studies have increasingly highlighted the aberrant expression of SLC16A1-AS1 in a variety of tumor types, where it functions as either an...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 122
SubjectTerms Apoptosis
Biomarkers
Brain cancer
Cancer biomarker
Cancer therapies
Cell cycle
Cell growth
CRISPR
Disease
Ferroptosis
Gene expression
Glioma
Human tumor
Kidney cancer
Liver cancer
Medical prognosis
Medical research
Metabolism
MicroRNAs
Review
Roles
SLC16A1-AS1
Squamous cell carcinoma
Therapeutic targets
Tumor suppressor genes
Tumorigenesis
Tumors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEB5CoJBL6LtO06JCb0XEki1ZOm5DQ1raHJoGchPSWKILqTfE3kP-fSXLXrKlJJfcjCUbeeaT5xs0D4CPKnJYK72jiKiigxIY1Y0PFD0rAxct9y4lOP84k6cX9bdLcXmn1VeKCcvlgbPgjpIF1ywgRu5ds1Y4q21ETctDiG8TIzWKNm92pqbzg0bJck6RUfKoT1YtZSLXNNWPE1RumaGxWv__KOa_kZJ3TM_JU9ifOCNZ5LU-gx3fPYcnuYvk7Qv4mq-StEkKFuzJKpDz78dMLhhdnDNy1eHPswWxXUuWQ0_mZEiSMyR7suzIsP6zuulfwsXJl1_Hp3TqkEBRaDVQXqPTGLirBXe2ZSGoUSnSYVCtdUypgFqUXiDWrcdGI5OIgfnWR1dFVq9gt1t1_g0QHSprK-5c05R1CNZ6lfr1OefQ28qVBbBZYAan8uGpi8WVGd0IJU0WsolCNqOQjSzg0-aZ61w8497Zn5MeNjNT4evxRoSDmeBgHoJDAYezFs20G3sTzXQEROQ6VQEfNsNxH6XDEdv51TrNiX-2hjHJC3idlb5ZSaVECuYTBagtOGwtdXukW_4ea3WzUkdKVJUHj_Fxb2GPZwzTqjyE3eFm7d9FTjS49yP8_wLuwAmU
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Ni9UwEA-6IngRv62uEsGbhG3aJk1O8lxcVtE9uC68W0gmiT5Y2_W17-B_b6Zf-kT2VpoEwsxkPpKZ3xDyWiUf1srgGACoFKBEznQdIoPA81gIXwSHBc6fz-TpRfVxLdbThVs3pVXOOnFQ1L4FvCM_Sqq2VjLZq_Lt1U-GXaPwdXVqoXGT3ELoMpTqer0EXDwtyOdCGSWPOrRtWI9cMUSRE0zuGaMBs_9_jua_-ZJ_GaCTe-Tu5DnS1cjq--RGaB6Q22MvyV8PyYfxC2lOMWWwo22k55-OuVxxtjrn9LKBL2crahtPN31H55JIOtZJdnTT0H73o912j8jFyfuvx6ds6pPAQGjVs6ICpyEWrhKFs57HqAbWSAdReeu4UhG0yIMAqHyAWgOXAJEHH1LAIsvH5KBpm_CUUB1La8vCubrOqxitDQq79jnnINjS5RnhM8EMTCDi2Mvi0gzBhJJmJLJJRDYDkY3MyJtlzdUIoXHt7HfIh2Umwl8PP9rtNzOdJoNuneYRIAVkFffCWW2TKvFFjEnEhM3I4cxFM53JzvyRoIy8WobTacInEtuEdodzkn6rOZdFRp6MTF92UiqBKX0iI2pPHPa2uj_SbL4PiN0818kxKvNn1-_rOblTjNLJyvyQHPTbXXiRfJ7evRwE-zerwAD6
  priority: 102
  providerName: ProQuest
Title Biological roles of SLC16A1-AS1 lncRNA and its clinical impacts in tumors
URI https://www.ncbi.nlm.nih.gov/pubmed/38555465
https://www.proquest.com/docview/3037868203
https://www.proquest.com/docview/3022571162
https://pubmed.ncbi.nlm.nih.gov/PMC10981830
https://doaj.org/article/183991fcc08641d5ba9a196d2ff10f5a
Volume 24
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bi9QwFD7sBcEX8W51HSL4JtEmbS59EJlZdlnFHWTWgcGXkqTJOjC2Ou2A--9NehkdGcSXUpq0CeeS850m5xyAl9JjWMWtxsYY6R0UR3AmrMPGkthRVlCrQ4Dz5ZRfzNMPC7Y4gKHcUU_Aeq9rF-pJzder1z9_3LzzCv-2VXjJ39TBZoU44xSH7HAM80M49pZJhIoGl-nvXQUhu6jhVDBMJRdDEM3eb-wYqjaf_z4Q-vdZyj-M0_lduNOjSjTuxOAeHNjyPtzq6kzePID33V3gBwrHCWtUOXT18ZTwMcHjK4JWpZlNx0iVBVo2NRrCJVEXQ1mjZYmazbdqXT-E-fnZ59ML3NdQwIZlssE0NTozjuqUUa0K4pxs2ca1cbJQmkjpTMZiy4xJC2tEZgg3xhFbWO_M8OQRHJVVaZ8AylyiVEK1FiJOnVPKylDRT2ttrEp0HAEZCJabPsF4qHOxyltHQ_K8I3LuiZy3RM55BK-273zv0mv8s_ck8GHbM6TGbh9U6-u817Q8QL6MOGO8s5aSgmmVKb_MFNQ5L35MRXAycDEfxC33htwLh0dDSQQvts1e08L2iSpttQl9_NonCOE0gscd07czSSQLx_1YBHJHHHamuttSLr-22bxJnHnQlMRP_2PgZ3CbdiKKk_gEjpr1xj73oKjRIzgUCzGC48nZ9NNs1P5aGLXS76-zyZdfTqYMkQ
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtQwcFSKEL0g3gQKGAlOyGrsxI5zQGgpVLt0uwfaSnsztmPDSm1SNlmh_hTfiJ3HwiLUW29RPIkmM-N5xPMAeC28D6u41dgYI3yA4gjOM-uwsSR2lBXU6lDgfDTj49P085zNt-DXUAsT0ioHndgq6qIy4R_5nle1meDeXiXvL37gMDUqnK4OIzQ6sTi0lz99yFa_m3z0_H1D6cGnk_0x7qcKYMNy0WCaGp0bR3XKqFYFcU60H8K1caJQmgjhTM5iy4xJC2uy3BBujCO2sN6954l_7w246Q1vHIK9bL4O8IhHMB4KcwTfq4MtDfXPKQ5d6xjmG8avnRHwP8f23_zMvwzewV2403uqaNSJ1j3YsuV9uNXNrrx8AJPuKvAYhRTFGlUOHU_3CR8RPDom6Kw0X2YjpMoCLZoaDSWYqKvLrNGiRM3qvFrWD-H0Wij4CLbLqrRPAOUuUSqhWmdZnDqnlBVhSqDW2liV6DgCMhBMmr5peZidcSbb4EVw2RFZeiLLlsiSR_B2_cxF17LjSugPgQ9ryNBuu71RLb_JfvfK4EbmxBnjA8CUFEyrXHnVVVDnvEgzFcHuwEXZ64Ba_pHYCF6tl_3uDUcyqrTVKsB4fZoRwmkEjzumrzFJBAsphCwCsSEOG6hurpSL722HcBLn3hFL4qdX4_USbo9PjqZyOpkdPoMd2kkqTuJd2G6WK_vc-1uNftEKOYKv172rfgNvT0I_
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Biological+roles+of+SLC16A1-AS1+lncRNA+and+its+clinical+impacts+in+tumors&rft.jtitle=Cancer+cell+international&rft.au=Liao%2C+Bing&rft.au=Wang%2C+Jialing&rft.au=Yuan%2C+Yalin&rft.au=Luo%2C+Hongliang&rft.date=2024-03-30&rft.issn=1475-2867&rft.eissn=1475-2867&rft.volume=24&rft.issue=1&rft.spage=122&rft_id=info:doi/10.1186%2Fs12935-024-03285-6&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1475-2867&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1475-2867&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1475-2867&client=summon